Skip to main content

Table 1 Characteristic variables in each newly diagnosed lung cancer adult patient

From: Integrated analysis of clinical, bioelectrical and functional variables in newly diagnosed lung cancer adult patients: pilot study

C

Variables

Biologic of patients

Biologic of the lung cancer

Bioelectrics

A

G

H

Po

ΔP

d-ECOG-fs

LCHV

LCS

sEGF (pg/mL)

sCYFRA 21–1 (ng/mL)

sCA72–4 (U/mL)

R

(Ω)

R/H

(Ω/m)

Xc

(Ω)

Xc/H

(Ω/m)

θ

(o)

1

57

M

1.74

76

2.7

1

SCLC

IV

293.78

1.03

2.00

403.0

231.61

48.9

28.10

6.7

2

73

M

1.63

70

11.1

2

EC

IIA

578.49

0.60

4.65

402.0

246.62

42.9

26.31

6.1

3

82

F

1.47

58

23.4

3

ADC

IV

789.15

3.68

8.20

610.0

414.96

44.3

30.13

4.2

4

69

M

1.59

57

−3.4

2

ADC

IV

1234.67

2.10

4.30

465.0

292.45

43.0

27.04

5.3

5

69

M

1.68

50

−26.5

3

ADC

IV

1009.34

6.20

5.98

478.0

284.52

21.7

12.91

3.6

6

58

M

1.63

61

−3.2

2

ADC

IIA

1238.24

0.98

3.56

523.0

320.85

56.6

34.72

6.2

7

71

M

1.70

73

4.3

1

ADC

IIA

187.45

2.37

4.99

404.0

237.64

51.4

30.23

6.6

8

53

M

1.68

56

−17.6

3

ADC

IV

970.06

11.76

28.34

561.0

333.92

65.9

39.22

6.7

9

71

F

1.67

78

16,4

2

ADC

IV

246.34

8.54

12.33

556.0

332.93

59.2

35.44

6.1

10

58

M

1.77

89

15,6

2

ADC

IIA

238.20

1.08

4.21

693.0

391.52

50.6

28.58

5.3

11

75

F

1.61

80

31.1

3

ADC

IV

303.67

6.45

8.43

571.0

354.65

49.4

30.68

6.7

12

79

M

1.79

87

10.1

2

nSCLC

IIIB

294.09

9.72

17.11

566.0

316.20

48.4

27.03

6.2

13

77

M

1.61

52

−14.8

3

EC

IV

667.32

5.49

7.81

514.0

318.01

44.3

27.51

6.3

14

74

M

1.63

58

−7.9

3

ADC

IIIB

1498.54

0.34

2.33

521.0

319.63

43.2

26.50

6.3

15

69

F

1.57

51

−10.5

3

CLC

IV

499.03

1.08

4.23

513.0

326.75

44.8

28.35

6.2

16

56

M

1.61

59

−3.3

1

ADC

IV

563.07

0.99

2.08

557.0

345.96

51.8

32.17

6.3

17

68

M

1.72

81

12.5

2

EC

IV

608.11

0.48

2.77

558.0

321.66

50.7

29.47

6.1

18

53

F

1.51

54

5.9

2

EC

IV

1201.18

5.60

5.16

611.0

399.42

45.4

29.67

5.3

19

77

F

1.54

42

−22.2

3

EC

IIIB

593.05

2.01

2.08

558.0

362.33

47.3

30.71

6.1

20

59

F

1.58

49

−15.5

3

ADC

IIIB

412.66

11.92

23.99

640.0

405.06

60.3

38.16

5.9

21

56

F

1.51

58

13.7

3

ADC

IV

1432.23

7.34

8.92

527.0

349.00

57.4

38.01

5.8

22

77

F

1.53

64

20.8

3

ADC

IV

289.09

0.87

2.34

572.0

373.85

50.9

33.36

6.2

23

58

M

1.69

83

20.3

3

EC

IV

674.08

0.69

3.09

568.0

336.09

52.3

30.94

6.4

  1. C Code of the patient, A Age, in years, G Gender, M Male gender, F Female gender, H Height, in m, Po Patient body weight, in kg, ΔP Relative change in unintentional body weight of each NDLCAPs, in %, d-ECOG-fs Degree of ECOG functional scale, ECOG Eastern Cooperative Oncology Group, LCHV Lung cancer histological variety, LCS Lung cancer stage, SCLC Small cell lung cancer, nSCLC Non-small cell lung cancer, ADC Adenocarcinoma, EC Epidermoide carcinoma, CLC Carcinoma of large cells and sEGF Serum Epidermal Growth Factor. sCYFRA 21–1 (serum CYFRA 21-1) and sCA72–4 (serum CA72–4) were tumor biomarkers. Code 1 (NPB), Code 2 (OMR), Code 3 (NHB), Code 4 (RSF), Code 5 (LGT), Code 6 (HMR), Code 7 (MBZ), Code 8 (ODR), Code 9 (OGC), Code 10 (JIRB), Code 11 (EGM), Code 12 (EPI), Code 13 (ITR), Code 14 (JRL), Code 15 (VTT), Code 16 (JCRO), Code 17 (RMP), Code 18 (ECP), Code 19 (EGC), Code 20 (NLB), Code 21 (OSP), Code 22 (CPI) and Code 23 (RGF)
Back to article page

Translational Medicine Communications

ISSN: 2396-832X

Contact us